查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992139

標靶治療市場：按產品類型、給藥途徑和最終用戶分類的全球市場預測 – 2026-2032 年

Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，標靶治療市場價值將達到 724.1 億美元，到 2026 年將成長至 773.5 億美元，到 2032 年將達到 1,218 億美元，複合年成長率為 7.71%。

主要市場統計數據
基準年 2025 724.1億美元
預計年份：2026年 773.5億美元
預測年份 2032 1218億美元
複合年成長率 (%) 7.71%

為領導者提供關於標靶治療不斷發展的生態系統的簡明概述，將科學突破與管理、監管和商業挑戰聯繫起來。

標靶治療透過將分子層面的洞見與治療方法設計相結合，正在重新定義臨床醫生和研發人員應對複雜疾病的方式。近年來，科學的進步推動了抗體藥物複合體、單株抗體、蛋白水解物和小分子抑制劑等治療方法從概念驗證階段邁向日益複雜的臨床計畫。因此，參與藥物發現、開發和商業化的相關人員必須適應更快的迭代周期、更深入的生物標記整合以及更敏感的監管對話。本文概述了影響該領域發展的關鍵因素，並提出了短期戰術性重點的預期。

科學創新與商業性創新的融合如何重塑標靶治療整體情況中的治療模式與營運重點。

近年來，標靶治療發生了變革性轉變，重塑了整體情況，加速了新治療方法的研發，同時也帶來了新的營運挑戰。蛋白質工程和偶聯化學技術的進步使抗體藥物複合體（ADC）成為選擇性遞送細胞毒性物質的主要治療方法。同時，單株抗體向全人源化和人源化結構的演進降低了免疫抗原性，從而延長了治療療程。此外，黏合劑和蛋白水解靶向嵌合體（PTC）等標靶蛋白分解技術的成熟，為調控以往難以攻克的標靶提供了新的途徑，拓展了治療選擇。

分析 2025 年將公佈的累積貿易和關稅趨勢及其對生物製藥採購、生產和患者獲取策略的連鎖影響。

2025年即將實施的累積關稅和貿易調整措施，為標靶治療的整個價值鏈增添了新的複雜性，影響採購、生產和分銷方面的決策。原料、特殊試劑和某些生物製藥成分的關稅變化增加了實際接收成本，促使採購團隊重新評估供應商。這些壓力通常會導致與契約製造的談判週期延長，並促使企業重新關注雙重採購策略，以維持臨床和商業性的連續性。此外，關稅帶來的成本壓力也影響新設施建設和技術投資的資金分配決策。

針對特定細分市場，結合產品模式、給藥途徑和最終用戶交付考慮因素，可以製定開發優先順序和商業化策略。

有效的細分能夠明確治療和商業回報的集中領域，有助於根據產品、給藥途徑和終端用戶領域對產品組合進行優先排序。從產品類型來看，此領域可分為抗體藥物複合體(ADC)、單株抗體、蛋白水解物和小分子抑制劑，每種產品都有其獨特的開發、生產和商業化需求。在抗體藥物複合體(ADC) 中，靶向 CD22 和 HER2 的藥物在有效載荷選擇和靶點結合策略方面存在差異，這會影響連接子的化學結構和細胞毒性有效載荷的選擇。單株抗體分為嵌合體、全人源型和人源化型，每種類型都會影響免疫抗原性風險、給藥頻率和監管要求。蛋白水解物包括分子黏合劑和 PROTAC，它們在選擇性光譜和臨床前評估途徑方面存在差異。另一方面，小分子抑制劑的範圍很廣，從 PARP 抑制劑到蛋白酶體抑制劑和蛋白酪氨酸激酶抑制劑，每一種都需要不同的藥理特性和伴隨診斷方法。

區域洞察重點介紹了美洲、歐洲、中東和非洲以及亞太地區的市場動態如何影響發展、進入和供應鏈策略。

區域趨勢影響從臨床開發策略到供應鏈配置和支付方合作等各方面，因此，地理洞察對於全球規劃至關重要。儘管美洲的監管路徑和支付體系各不相同，但該地區通常在創新治療方法的早期應用和基於價值的合約試點計畫中發揮主導作用。因此，製造商應優先考慮能夠產生可靠臨床證據並與支付方合作的框架，以證明其療效和長期結果的可比較性。北美的生產能力和先進的臨床試驗基礎設施支持複雜治療方法的快速患者招募，但國內採購和關稅因素可能會影響後期生產基地的選擇。

產業領導者正在投資策略性企業活動和能力建設，以將技術創新轉化為具有臨床意義的治療方法和永續的商業性優勢。

產業領導企業正在實施一系列策略措施，以最大限度地發揮標靶治療的潛力，同時應對相關的科學和商業性複雜性。許多機構正在加速投資於標準化偶聯技術、抗體工程和分解化學的平台，以降低技術風險並縮短臨床試驗時間。另一些機構則與生技公司、學術機構和合約開發組織 (CDO) 建立合作關係，以利用專家能力，而無需承擔全部內部開發成本。這些夥伴關係模式支持靈活的產能擴展，並能夠快速回應每種治療方法不斷變化的需求。

為標靶治療的領導者提供切實可行的跨部門建議，以協調生物標記主導的開發、具有韌性的供應鏈和以患者為中心的商業化。

致力於最大化標靶治療價值的領導者應採取務實且跨領域的措施，將科學優先事項與商業性現實和供應鏈韌性相結合。首先，在臨床開發早期階段整合生物標記策略和衛生經濟學，以確保試驗能夠產生支付方所需的證據。協調這些功能可以減少後期延誤，並強化價值主張。其次，透過認證區域契約製造合作夥伴並設計能夠實現關鍵組件互換性的平台，實現採購和生產多元化。這可以降低關稅衝擊和短期供應中斷帶來的風險。

透明的混合方法研究框架，結合相關人員訪談、臨床和專利分析、供應鏈映射和基於情境的檢驗，確保了可靠的見解。

本研究整合了定性和定量方法，結合與關鍵相關人員的對話、系統的二手資料研究和技術綜述，從而對標靶治療趨勢有了更深入的了解。主要研究包括對臨床研究人員、監管專家、生產負責人、支付方和分銷專家的深入訪談，揭示了實際操作中的限制因素和新興的最佳實踐。透過這些對話進行主題編碼，識別出反覆出現的營運挑戰，例如低溫運輸脆弱性、監管差異以及支付方要求的證據要求。

對科學進步、供應鏈考量和支付方期望如何決定標靶治療的成功與否進行全面分析和策略性展望。

總之，標靶治療領域正處於科學創新、營運複雜性和商業性審查交會的十字路口。抗體藥物複合體、單株抗體、蛋白水解劑和小分子抑制劑的進步拓展了研發人員可用的工具箱，但要實現治療和商業預期，需要研發、生產、監管和支付方等各部門的協調努力。貿易和關稅波動帶來了新的營運挑戰，迫使企業制定更詳細的供應鏈計畫和策略採購決策；同時，監管和報銷框架的區域差異也要求企業採取個人化的市場准入策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章標靶治療市場：依產品類型分類

  • 抗體藥物複合體
    • CD22標靶
    • HER2靶點
  • 單株抗體
    • 嵌合體
    • 完全人形
    • 人性化
  • 蛋白質分解劑
    • 分子黏合劑
    • PROTAC
  • 小分子抑制劑
    • PARP抑制劑
    • 蛋白酶體抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章標靶治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章標靶治療市場：依最終用戶分類

  • 居家醫療
  • 醫院藥房
  • 零售藥房
  • 專科診所

第11章標靶治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章標靶治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章標靶治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國標靶治療市場

第15章：中國標靶治療市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-CA7E340319CF

The Targeted Therapy Market was valued at USD 72.41 billion in 2025 and is projected to grow to USD 77.35 billion in 2026, with a CAGR of 7.71%, reaching USD 121.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 72.41 billion
Estimated Year [2026] USD 77.35 billion
Forecast Year [2032] USD 121.80 billion
CAGR (%) 7.71%

A concise orientation to the evolving targeted therapy ecosystem that connects scientific breakthroughs with operational, regulatory, and commercial imperatives for leaders

Targeted therapies are redefining how clinicians and developers approach complex diseases by aligning molecular insights with therapeutic design. Recent scientific advances have pushed modalities such as antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors from proof-of-concept into increasingly sophisticated clinical programs. As a result, stakeholders across discovery, development, and commercialization must adapt to faster iteration cycles, deeper biomarker integration, and more nuanced regulatory dialogues. This introduction frames the critical forces shaping the field and sets expectations for near-term tactical priorities.

Investors and R&D leaders now judge programs not only on biological rationale but also on manufacturability, supply chain robustness, and reimbursement pathways. Clinical teams emphasize patient selection and companion diagnostics to improve trial efficiency and therapeutic impact, while manufacturing groups prioritize platform consistency and scalable processes to reduce variability. In parallel, payers and health systems increasingly demand real-world evidence and outcomes-based contracting to justify premium pricing for novel modalities. These converging pressures create both friction and opportunity: organizations that align scientific excellence with operational execution will capture disproportionate value.

Transitioning from early discovery to widespread adoption requires deliberate alignment across cross-functional teams. This report begins by outlining transformational shifts in science and market structure, then explores regulatory and trade headwinds, segment-level implications, regional dynamics, and strategic recommendations intended to inform immediate actions and longer-term planning.

How converging scientific, regulatory, and commercial innovations are reshaping therapeutic modalities and operational priorities across the targeted therapy landscape

The last several years have produced transformative shifts that are remapping the targeted therapy landscape, accelerating novel modalities while raising new operational imperatives. Technological advances in protein engineering and conjugation chemistry have elevated antibody drug conjugates into a leading modality for delivering cytotoxic payloads selectively, while monoclonal antibody evolution toward fully human and humanized constructs has reduced immunogenicity and enabled longer treatment windows. Simultaneously, the maturation of targeted protein degradation-through molecular glues and proteolysis targeting chimeras-introduces routes to modulate previously intractable targets, broadening the therapeutic opportunity set.

These scientific gains intersect with innovations in small molecule design, where tailored inhibitors such as PARP, proteasome, and tyrosine kinase agents offer complementary mechanisms for multi-modal regimens. At the same time, digital tools and artificial intelligence accelerate lead identification and predictive modeling, shortening development cycles and improving candidate selection. Regulatory frameworks are adapting to these modalities by offering more targeted guidance on combination approaches, biomarker-driven approvals, and adaptive trial designs, yet variability in regional expectations is prompting sponsors to design programs with parallel regulatory engagement.

Commercially, payers and providers are demanding clearer evidence of comparative effectiveness and value-based pricing models, which drives closer alignment between clinical development and health economics planning. Manufacturing and cold-chain logistics improvements are enabling new route-of-administration strategies, particularly increased attention to subcutaneous and home-administered formulations that improve patient convenience and lower system costs. The net effect is a landscape where innovation is rapid, but success increasingly depends on integrated scientific, regulatory, and commercial execution.

Analyzing the cumulative trade and tariff dynamics announced for 2025 and their cascading effects on biopharmaceutical sourcing, manufacturing, and patient access strategies

The introduction of cumulative tariffs and trade adjustments announced for 2025 has introduced a new layer of complexity across the targeted therapy value chain, affecting sourcing, manufacturing, and distribution decisions. Tariff changes on raw materials, specialized reagents, and certain biologics-related components increase effective landed costs and prompt procurement teams to reassess supplier footprints. These pressures often translate into longer negotiation cycles with contract manufacturers and a renewed emphasis on dual-sourcing strategies to maintain clinical and commercial continuity. Moreover, tariff-driven cost pressures influence capital allocation decisions for new facility builds and technology investments.

Manufacturers facing increased import duties for key inputs have adopted several mitigation strategies, including reshoring select production steps closer to end markets, qualifying local suppliers where possible, and redesigning supply chains to reduce reliance on tariff-exposed nodes. Regulatory harmonization efforts and free trade agreements remain uneven, so companies must navigate a patchwork of customs procedures and compliance requirements that can delay batch release and increase lead times. For programs reliant on time-sensitive biologics or cold-chain logistics, even modest tariff-related delays can disrupt clinical trial timelines and product launches, which in turn impacts forecasting and inventory policies at distributors and hospitals.

In response, senior leaders are recalibrating vendor contracts to include tariff pass-through clauses and investing in supply chain transparency tools to model exposure across scenarios. Strategic sourcing now requires closer collaboration between commercial, regulatory, and procurement teams to optimize total landed cost while preserving product integrity and patient access. The cumulative effect of these trade measures is to accelerate existing trends toward regionalization of production and enhanced supply chain resilience, with implications for pricing strategies, partner selection, and manufacturing footprint optimization.

Segment-focused insights that integrate product modality, administration route, and end-user delivery considerations to inform development prioritization and commercialization tactics

Effective segmentation clarifies where therapeutic and commercial returns will concentrate and informs portfolio prioritization across product, administration route, and end-user domains. When viewed through product type, the landscape differentiates antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors, each with distinct development, manufacturing, and commercialization demands. Within antibody drug conjugates, agents directed at CD22 and HER2 represent divergent payload selection and target engagement strategies that influence linker chemistry and cytotoxic payload choices. Monoclonal antibodies subdivide into chimeric, fully human, and humanized formats, affecting immunogenicity risk, dosing frequency, and regulatory expectations. Protein degraders encompass molecular glues and PROTACs, which differ in selectivity profiles and preclinical assessment pathways, while small molecule inhibitors range from PARP inhibitors to proteasome and tyrosine kinase inhibitors, each requiring different pharmacology and companion diagnostic approaches.

Routes of administration add another layer of strategic differentiation, spanning intravenous, oral, and subcutaneous delivery. Intravenous therapies often necessitate hospital-based administration and complex cold-chain logistics, while oral agents increase outpatient convenience and adherence considerations. Subcutaneous formulations are gaining prominence as a patient-friendly alternative that can reduce infusion center burden and enable home-based care models. End-user segmentation further refines go-to-market and support needs, with home care, hospital pharmacy, retail pharmacy, and specialty clinics each presenting unique distribution, reimbursement, and patient support requirements. Home care models require robust patient education and remote monitoring, hospital pharmacy environments demand streamlined formulary access and inpatient logistics, retail pharmacies offer broad outpatient reach but require clear dispensing pathways, and specialty clinics provide concentrated clinical expertise and can facilitate complex care pathways.

Understanding the intersection across these dimensions enables sponsors to tailor development and commercialization tactics, align clinical trial designs with likely real-world administration settings, and structure stakeholder engagement plans that reflect where and how therapies will be delivered and reimbursed.

Regional intelligence spotlighting how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics influence development, access, and supply chain strategies

Regional dynamics shape everything from clinical development strategies to supply chain configuration and payer interactions, making geographic insight indispensable for global planning. In the Americas, regulatory pathways and payer systems are highly varied, but the region often leads in early adoption of innovative therapies and value-based contracting pilots; manufacturers should therefore prioritize robust clinical evidence generation and payer engagement frameworks that demonstrate comparative effectiveness and long-term outcomes. North American manufacturing capacity and advanced clinical trial infrastructure support rapid enrollment for complex modalities, but domestic sourcing and tariff considerations can influence where late-stage production is sited.

Europe, Middle East & Africa present a mosaic of regulatory expectations and reimbursement mechanisms that require tailored market entry strategies. European health technology assessment bodies frequently demand rigorous health economic data and may negotiate centralized procurement for high-cost therapies, while reimbursement timelines can vary substantially between markets. The Middle East and Africa offer pockets of high unmet need and concentrated procurement initiatives, yet accessibility and local regulatory capacity vary widely, prompting sponsors to adopt differentiated commercial models and targeted access programs.

Asia-Pacific continues to expand clinical development capacity and local manufacturing capabilities, with several markets emphasizing domestic innovation and regulatory modernization. Countries across the region are increasingly receptive to data generated from local patient populations and are investing in infrastructure that supports large-scale oncology and specialty care trials. Pricing and reimbursement policies differ markedly between public and private systems, so sponsors should design regional strategies that balance localized evidence generation with efficient regulatory pathways. Across regions, the convergence of digital health adoption and decentralized trial methodologies presents opportunities to harmonize patient recruitment, monitoring, and long-term outcomes collection at scale.

Strategic corporate moves and capability investments industry leaders are deploying to convert modality innovation into clinically meaningful therapies and sustainable commercial advantage

Industry leaders are deploying a range of strategic moves to capture the promise of targeted therapies while managing the attendant scientific and commercial complexity. Many organizations are accelerating platform investments that standardize conjugation technologies, antibody engineering, and degradation chemistries to reduce technical risk and shorten time to clinic. Others are forging collaborations across biotech partners, academic centers, and contract development organizations to access specialized capabilities without assuming the full cost of in-house development. These partnership models support flexible capacity scaling and enable rapid response as modality-specific demand shifts.

Commercial strategies now emphasize integrated launch planning that brings clinical development, regulatory engagement, health economics, and market access teams together earlier in the lifecycle. Leaders invest in real-world evidence generation and outcomes tracking to demonstrate value to payers and providers, and they deploy patient support services to promote adherence and optimize clinical outcomes. On the manufacturing front, companies are diversifying supplier bases, qualifying secondary manufacturing sites, and expanding fill-finish capabilities to mitigate supply disruption risks.

Pipeline management has become more selective, with sponsors prioritizing indications and combinations that maximize therapeutic differentiation and align with feasible reimbursement pathways. Talent strategies focus on hiring scientists and executives with cross-functional experience in biologics, regulatory affairs, and commercial operations. The net effect is a more disciplined, partnership-driven, and execution-focused industry posture that seeks to translate scientific promise into durable therapeutic and commercial success.

Actionable cross-functional recommendations to align biomarker-driven development, resilient supply chains, and patient-centric commercialization for leaders in targeted therapy

Leaders seeking to maximize value in targeted therapy should adopt a set of actionable, cross-functional measures that align scientific priorities with commercial realities and supply chain resilience. First, integrate biomarker strategy and health economics early in clinical development to ensure trials generate the evidence payers require; connecting these functions reduces later-stage delays and strengthens value narratives. Second, diversify sourcing and manufacturing by qualifying regional contract manufacturing partners and by designing platforms that permit interchangeability of critical components; this reduces exposure to tariff shocks and short-term supply interruptions.

Third, prioritize patient-centric administration strategies by investing in subcutaneous formulation development and patient support infrastructure that enable home-based care where clinically appropriate. Fourth, pursue strategic collaborations to access specialized modalities such as molecular glues or PROTAC chemistry while preserving optionality through staged investment and clear milestone gating. Fifth, engage proactively with regulatory authorities across key jurisdictions to align on adaptive trial designs and biomarker-driven approval pathways, reducing the risk of divergent requirements and costly trial amendments.

Finally, operationalize data and analytics to monitor supply chain exposure, clinical trial progress, and real-world outcomes in near real time; these capabilities enable faster course corrections and more informed commercial rollouts. Collectively, these actions help organizations navigate complexity, preserve optionality, and accelerate the translation of scientific advances into patient benefit and sustained commercial performance.

A transparent mixed-methods research framework combining stakeholder interviews, clinical and patent analysis, supply chain mapping, and scenario-based validation to ensure robust insights

This research synthesizes qualitative and quantitative approaches to produce a nuanced view of targeted therapy dynamics, combining primary stakeholder engagement with structured secondary analysis and technical review. Primary research included in-depth interviews with clinical investigators, regulatory specialists, manufacturing leaders, payers, and distribution experts to surface practical constraints and emerging best practices. These dialogues informed thematic coding and identified recurring operational pain points such as cold-chain vulnerability, regulatory heterogeneity, and payer evidence expectations.

Secondary analysis encompassed peer-reviewed literature, clinical trial registries, patent filings, and publicly available regulatory guidance to validate scientific trends and modality-specific technical requirements. Supply chain mapping leveraged public customs data and industry logistics reporting to trace typical component flows and identify tariff-sensitive nodes. Additionally, product development case studies and manufacturing due diligence informed assessments of platform readiness and scale-up risk.

Analytical methods included cross-sectional synthesis to compare modality characteristics, scenario modeling to evaluate tariff and supply disruption impacts, and triangulation across data sources to ensure robustness. Wherever possible, findings were stress-tested against recent regulatory decisions, clinical readouts, and announced capacity investments to ensure recommendations reflect operational realities. This mixed-methods approach offers a replicable framework for translating scientific advances into strategic priorities while acknowledging uncertainty and preserving managerial flexibility.

Synthesis and strategic outlook summarizing how scientific advances, supply chain considerations, and payer expectations will determine success in targeted therapy

In closing, the targeted therapy field stands at an inflection point where scientific ingenuity meets operational complexity and commercial scrutiny. Advances across antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors have expanded the toolkit available to developers, but realizing therapeutic and commercial promise requires coordinated action across development, manufacturing, regulatory, and payer engagement functions. Trade and tariff changes add a new operational layer that compels more granular supply chain planning and strategic sourcing decisions, while regional heterogeneity in regulatory and reimbursement frameworks necessitates tailored go-to-market approaches.

Organizations that invest early in integrated evidence generation, diversify manufacturing footprints, and design patient-centered administration strategies will improve their odds of successful adoption. Partnerships remain a powerful mechanism to access specialized capabilities and to share risk, and leaders who combine platform investments with selective external collaborations are best positioned to scale efficiently. Ultimately, targeted therapies will continue to reshape treatment paradigms, but success will hinge on the ability to translate molecular innovation into reproducible clinical outcomes, reliable supply, and validated value to payers and providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Therapy Market, by Product Type

  • 8.1. Antibody Drug Conjugates
    • 8.1.1. Cd22 Directed
    • 8.1.2. Her2 Directed
  • 8.2. Monoclonal Antibodies
    • 8.2.1. Chimeric
    • 8.2.2. Fully Human
    • 8.2.3. Humanized
  • 8.3. Protein Degraders
    • 8.3.1. Molecular Glues
    • 8.3.2. Protacs
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Parp Inhibitors
    • 8.4.2. Proteasome Inhibitors
    • 8.4.3. Tyrosine Kinase Inhibitors

9. Targeted Therapy Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Targeted Therapy Market, by End User

  • 10.1. Home Care
  • 10.2. Hospital Pharmacy
  • 10.3. Retail Pharmacy
  • 10.4. Specialty Clinic

11. Targeted Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Targeted Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Targeted Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Targeted Therapy Market

15. China Targeted Therapy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Amgen Inc.
  • 16.7. Astellas Pharma Inc.
  • 16.8. AstraZeneca PLC
  • 16.9. Bayer AG
  • 16.10. BeiGene, Ltd.
  • 16.11. Biogen Inc.
  • 16.12. BioMarin Pharmaceutical Inc.
  • 16.13. Bristol Myers Squibb Company
  • 16.14. Eisai Co., Ltd.
  • 16.15. Eli Lilly and Company
  • 16.16. Exelixis, Inc.
  • 16.17. F. Hoffmann-La Roche AG
  • 16.18. Genmab A/S
  • 16.19. Gilead Sciences, Inc.
  • 16.20. GlaxoSmithKline plc
  • 16.21. Incyte Corporation
  • 16.22. Johnson & Johnson Services, Inc.
  • 16.23. Merck & Co., Inc.
  • 16.24. Merck KGaA
  • 16.25. Novartis AG
  • 16.26. Pfizer Inc.
  • 16.27. Regeneron Pharmaceuticals, Inc.
  • 16.28. Sanofi S.A.
  • 16.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 149. GCC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 150. GCC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 173. G7 TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 174. G7 TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 181. NATO TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 182. NATO TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)